MedTrace Logo

Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC

NCT03813394 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-11-22

No results posted yet for this study

Summary

This is a single center, randomized, phase Ib/II open-label study of pembrolizumab (pembro or MK-3475) with or without bevacizumab in patients with recurrent non-curable or metastatic nasopharyngeal carcinoma (NPC).

Conditions

  • Locally Recurrent Cancer
  • Metastatic Nasopharyngeal Cancer

Interventions

DRUG

pembrolizumab

-Pembrolizumab in Solution for Injection

DRUG

bevacizumab

* Bevacizumab in Concentrate for Solution * Bevacizumab in Concentrate for Solution

Sponsors & Collaborators

Principal Investigators

  • Boon Cher Goh · National University Hospital, Singapore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2024-07-31
Completion
2025-06-01

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03813394 on ClinicalTrials.gov